Navigation Links
Drug Delivery in Cancer - Technologies, Markets and Companies 2013

DUBLIN, June 17, 2013 /PRNewswire/ --

Research and Markets ( has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.

Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.

Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.

Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.

Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described.

Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors.

The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2012-2022 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.

Profiles of 227 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 256 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 10 figures.

Key Topics Covered:

Part I: Technologies & Markets

Executive Summary

1. Introduction to cancer therapy

2. Innovative treatments for cancer

3. Drug delivery systems for cancer

4. Delivery of Biological Therapies for Cancer

5. Delivery strategies according to cancer type and location

6. Cancer drug delivery markets

7. References

Part II: Companies

8. Companies involved in cancer drug delivery

For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
2. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
3. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
4. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
5. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
6. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
7. US Intranasal Drug Delivery Industry
8. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
9. GeNO LLC Receives Two Additional Patents For Inhaled Nitric Oxide Drug Delivery
10. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
11. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
Post Your Comments:
(Date:11/25/2015)... -- Linden Care, LLC, a retail specialty pharmacy focused on ... from chronic pain, said today that it is disappointed ... enjoining Express Scripts from unilaterally terminating the Pharmacy Provider ... --> The company said that it ... --> --> In the ...
(Date:11/25/2015)... -- ARKRAY USA , Inc., a leader ... the accuracy of its blood glucose meter systems. Last ... and Cardiovascular Disease in Los Angeles ... 01 meter and the Assure ® Prism ... accurately measure glucose levels in blood is essential for ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... Dr. Thomas Dunlap and Dr. Patrick ... Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital ... present in similar ways and require time-critical intervention to avoid large area heart damage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) ... supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk ...
(Date:11/26/2015)... Las Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... holiday shopping strategy. Many customers choose to buy during the Black Friday and ... holiday gifts. Shoppers don’t need to search the Internet high and low to find ...
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
Breaking Medicine News(10 mins):